Clinical Observation of Tripterygium Tablets Combined with Compound α-Keto Acid Tablets in the Treat-ment of Diabetic Nephropathy / 中国药房

ABSTRACT

OBJECTIVE:To observe therapeutic efficacy and safety of Tripterygium tablets combined with Compound α-keto acid tablets in the treatment of diabetic nephropathy(DN)patients. METHODS:A total of 186 DN patients were randomly divided into control group(93 cases)and study group group(93 cases). Based on routine treatment,control group was given Tripterygium tablet 20 mg orally,3 times a day;study group was additionally given Compound α-keto acid tablet 3.78 g orally,3 times a day, on the basis of control group. Both groups were treated for consecutive 3 months. Clinical efficacies of 2 groups were observed, and the levels of renal function indexes (Scr,BUN,CysC,GFR,24 h urine protein),renal interstitial fibrosis indexes (Hcy, VEGF,HGF,TGF-β1) and oxidative stress indexes (T-AOC,SOD,AOPP,MDA),the occurrence of ADR were also observed before and after treatment. RESULTS:No patient withdrew from the experiment in 2 groups,and all completed the treatment. Total response rate of study group (91.39%) was significantly higher than that of control group (80.65%),with statistical significance (P<0.05). After treatment,the levels of Scr,BUN,CysC and 24 h urine protein,Hcy,VEGF,TGF-β1,AOPP and MDA in 2 groups were significantly lower than before,and the study group was significantly lower than the control group;the levels of GFR,HGF,T-AOC and SOD in 2 groups were significantly higher than before treatment,and the study group was significantly higher than the control group,with statistical significance(P<0.05). There was no statistical significance in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS:Tripterygium tablets combined with Compound α-keto acid tablets show significant therapeutic efficacy for DN patients but do not increase the occurrence of ADR.